{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:57:36Z","timestamp":1785275856505,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of some chemotherapy regimens. Lithium has been suggested for CIPN in some animal studies. We aimed to study lithium\u2019s preventive effect on CIPN in breast cancer patients treated with taxanes and platinum-based medications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>A double-blind placebo-controlled randomized clinical trial (RCT) was implemented on 36 breast cancer patients in two equal-size groups by block randomization. Participants in both groups consumed daily tablets, either placebo or lithium (300\u2009mg), for 5 days in each course of chemotherapy. The tablets were prescribed 1 day before the start of chemotherapy. The electromyography (EMG) and nerve-conduction-velocity (NCV) tests were achieved before the first chemotherapy, 3 and 9 months after the treatment. The changes and signs or symptoms of CIPN, such as numbness, tingling, freezing, sensitivity to touch, muscle weakness, fibrillation, and knee and elbow reflex disorders, were recorded by examination. The trend of outcome changes was compared between two groups during the 9 months of study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In both groups, neurologic signs and symptoms were exacerbated during the first 3 months and improved up to the ninth month of study. Results showed significant changes of all EMG-NCV variables during the 9 months of research in each group (<jats:italic>P<\/jats:italic> &lt;\u20090.001), but the interaction of time and group effect was not significant in none of those indices. All symptoms changed significantly over the study time (<jats:italic>P<\/jats:italic> &lt;\u20090.001) without significant statistical difference between the two groups (<jats:italic>P<\/jats:italic>=0.352). No side effect was found during the study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The study showed that 300\u2009mg lithium prescription once daily for 5 days might not effectively prevent CIPN in breast cancer patients. Evaluation of lithium effect on CIPN on different cancers in future studies is suggested.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Iranian Registry of Clinical Trials <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/en.irct.ir\/trial\/29979\">IRCT20160813029327N10<\/jats:ext-link>.\u00a0\u00a0Registration date: May 16, 2018.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-021-05800-w","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T12:03:17Z","timestamp":1637755397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Lithium and preventing chemotherapy-induced peripheral neuropathy in breast cancer patients: a placebo-controlled randomized clinical trial"],"prefix":"10.1186","volume":"22","author":[{"given":"S.","family":"Najafi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Heidarali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rajabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Omidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zayeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6938-467X","authenticated-orcid":false,"given":"S.","family":"Haghighat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"issue":"7","key":"5800_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.5603\/GP.2016.0036","volume":"87","author":"D I\u017cycki","year":"2016","unstructured":"I\u017cycki D, Niezgoda AA, Ka\u017amierczak M, Piorunek T, I\u017cycka N, Karaszewska B, et al. Chemotherapy-induced peripheral neuropathy\u2014diagnosis, evolution and treatment. Ginekologia polska. 2016;87(7):516\u201321. https:\/\/doi.org\/10.5603\/GP.2016.0036.","journal-title":"Ginekologia polska."},{"issue":"suppl_4","key":"5800_CR2","first-page":"iv45","volume":"14","author":"W Grisold","year":"2012","unstructured":"Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012;14(suppl_4):iv45\u201354.","journal-title":"Neuro Oncol"},{"issue":"18","key":"5800_CR3","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","volume":"32","author":"DL Hershman","year":"2014","unstructured":"Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941\u201367. https:\/\/doi.org\/10.1200\/JCO.2013.54.0914.","journal-title":"J Clin Oncol."},{"key":"5800_CR4","volume-title":"Chemotherapy-induced peripheral neuropathy: an update on the current understanding [version 1; referees: 2 approved].","author":"J Addington","year":"2016","unstructured":"Addington J, Freimer M. Chemotherapy-induced peripheral neuropathy: an update on the current understanding [version 1; referees: 2 approved]. . PubMed Abstract| Publisher Full Text| Free Full Text. 2016."},{"issue":"2","key":"5800_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10549-016-3939-0","volume":"159","author":"T Bao","year":"2016","unstructured":"Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat. 2016;159(2):327\u201333. https:\/\/doi.org\/10.1007\/s10549-016-3939-0.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"5800_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4103\/2347-5625.170977","volume":"3","author":"J Schloss","year":"2016","unstructured":"Schloss J, Colosimo M, Vitetta L. New insights into potential prevention and management options for chemotherapy-induced peripheral neuropathy. Asia Pac J Oncol Nurs. 2016;3(1):73\u201385. https:\/\/doi.org\/10.4103\/2347-5625.170977.","journal-title":"Asia Pac J Oncol Nurs."},{"key":"5800_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fphar.2013.00156","volume":"4","author":"Y Han","year":"2013","unstructured":"Han Y, Smith MT. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front Pharmacol. 2013;4:156. https:\/\/doi.org\/10.3389\/fphar.2013.00156.","journal-title":"Front Pharmacol"},{"issue":"20","key":"5800_CR8","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1200\/JCO.2012.44.8738","volume":"31","author":"DL Hershman","year":"2013","unstructured":"Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol. 2013;31(20):2627\u201333. https:\/\/doi.org\/10.1200\/JCO.2012.44.8738.","journal-title":"J Clin Oncol."},{"issue":"10","key":"5800_CR9","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1200\/JCO.2013.52.0536","volume":"32","author":"CL Loprinzi","year":"2014","unstructured":"Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB\/Alliance). J Clin Oncol. 2014;32(10):997\u20131005. https:\/\/doi.org\/10.1200\/JCO.2013.52.0536.","journal-title":"J Clin Oncol."},{"issue":"12","key":"5800_CR10","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/cncr.28654","volume":"120","author":"AD Leal","year":"2014","unstructured":"Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, et al. North Central Cancer Treatment Group\/Alliance trial N08CA\u2014the use of glutathione for prevention of paclitaxel\/carboplatin-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled study. Cancer. 2014;120(12):1890\u20137. https:\/\/doi.org\/10.1002\/cncr.28654.","journal-title":"Cancer."},{"issue":"11","key":"5800_CR11","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s00520-010-1018-3","volume":"19","author":"LA Kottschade","year":"2011","unstructured":"Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Supportive Care Cancer. 2011;19(11):1769\u201377. https:\/\/doi.org\/10.1007\/s00520-010-1018-3.","journal-title":"Supportive Care Cancer."},{"issue":"4","key":"5800_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3390\/nu10040398","volume":"10","author":"E Wesselink","year":"2018","unstructured":"Wesselink E, Winkels RM, Van Baar H, Geijsen AJ, Van Zutphen M, Van Halteren HK, et al. Dietary intake of magnesium or calcium and chemotherapy-induced peripheral neuropathy in colorectal cancer patients. Nutrients. 2018;10(4):398. https:\/\/doi.org\/10.3390\/nu10040398.","journal-title":"Nutrients."},{"issue":"3","key":"5800_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.5114\/wo.2012.29296","volume":"16","author":"K Brzezi\u0144ski","year":"2012","unstructured":"Brzezi\u0144ski K. Chemotherapy-induced peripheral neuropathy. Part II. Prevention. Contemp Oncol. 2012;16(3):258\u201361. https:\/\/doi.org\/10.5114\/wo.2012.29296.","journal-title":"Contemp Oncol."},{"issue":"1","key":"5800_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-12-355","volume":"12","author":"Z Ghoreishi","year":"2012","unstructured":"Ghoreishi Z, Esfahani A, Djazayeri A, Djalali M, Golestan B, Ayromlou H, et al. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer. 2012;12(1):1\u20138. https:\/\/doi.org\/10.1186\/1471-2407-12-355.","journal-title":"BMC Cancer."},{"issue":"11","key":"5800_CR15","first-page":"1020","volume":"30","author":"N Majithia","year":"2016","unstructured":"Majithia N, Loprinzi CL, Smith TJ. New practical approaches to chemotherapy-induced neuropathic pain: prevention, assessment, and treatment. Oncology (Williston Park, NY). 2016;30(11):1020\u20139.","journal-title":"Oncology (Williston Park, NY)"},{"key":"5800_CR16","volume-title":"Basic and clinical pharmacology","author":"G Katzung Bertram","year":"2012","unstructured":"Katzung Bertram G, Masters Susan B, Trevor AJ. Basic and clinical pharmacology. San Francisco: McGraw-Hill Companies; 2012."},{"issue":"6","key":"5800_CR17","first-page":"373","volume":"50","author":"H Alimoradi","year":"2012","unstructured":"Alimoradi H, Pourmohammadi N, Mehr SE, Hassanzadeh G, Hadian MR, Sharifzadeh M, et al. Effects of lithium on peripheral neuropathy induced by vincristine in rats. Acta Medi Iran. 2012;50(6):373\u20139.","journal-title":"Acta Medi Iran."},{"key":"5800_CR18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.neuroscience.2013.09.033","volume":"254","author":"M Gao","year":"2013","unstructured":"Gao M, Yan X, Weng H-R. Inhibition of glycogen synthase kinase 3beta activity with lithium prevents and attenuates paclitaxel-induced neuropathic pain. Neuroscience. 2013;254:301\u201311. https:\/\/doi.org\/10.1016\/j.neuroscience.2013.09.033.","journal-title":"Neuroscience."},{"issue":"11","key":"5800_CR19","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1096\/fj.12-214643","volume":"26","author":"M Mo","year":"2012","unstructured":"Mo M, Erdelyi I, Szigeti-Buck K, Benbow JH, Ehrlich BE. Prevention of paclitaxel-induced peripheral neuropathy by lithium pretreatment. FASEB J. 2012;26(11):4696\u2013709. https:\/\/doi.org\/10.1096\/fj.12-214643.","journal-title":"FASEB J."},{"issue":"7","key":"5800_CR20","doi-asserted-by":"publisher","first-page":"7322","DOI":"10.18632\/oncotarget.23467","volume":"9","author":"RJ Wadia","year":"2018","unstructured":"Wadia RJ, Stolar M, Grens C, Ehrlich BE, Chao HH. The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget. 2018;9(7):7322\u201331. https:\/\/doi.org\/10.18632\/oncotarget.23467.","journal-title":"Oncotarget."},{"key":"5800_CR21","volume-title":"Koda-kimble and young\u2019s applied therapeutics","author":"BK Alldredge","year":"2013","unstructured":"Alldredge BK, Corelli RL, Ernst ME, Guglielmo B, Jacobson P, Kradjan W, et al. Koda-kimble and young\u2019s applied therapeutics. Philadelphia: Lippincott Williams & Wilkins; 2013."},{"key":"5800_CR22","volume-title":"Indication and dose for lithium carbonate: National Institute for Health and Care Excellence","author":"National Institute for Health and Care Excellence (NICE)","year":"2021","unstructured":"National Institute for Health and Care Excellence (NICE). Indication and dose for lithium carbonate: National Institute for Health and Care Excellence; 2021 [cited 2021]. Available from: https:\/\/bnf.nice.org.uk\/drug\/lithium-carbonate.html."},{"key":"5800_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.critrevonc.2015.11.014","volume":"98","author":"C Brami","year":"2016","unstructured":"Brami C, Bao T, Deng G. Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: a systematic review. Crit Rev Oncol Hematol. 2016;98:325\u201334. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.11.014.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05800-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05800-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05800-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T12:22:31Z","timestamp":1637756551000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05800-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5800"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05800-w","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]},"assertion":[{"value":"27 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Islamic Azad University of Pharmaceutical Sciences (IAUPS), Tehran, Iran (No: 374). It was registered in the IRCT center (IRCT20160813029327N10).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"835"}}